Drug Interaction Report

Abrocitinib and Repotrectinib: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Abrocitinib

Cibinqo Cibinqo®
+

Repotrectinib

Augtyro
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 10, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 67 documented Abrocitinib interactions, 46 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Effects may be stronger
The Bottom Line
Abrocitinib can raise repotrectinib levels and side-effect risk, so this combination is usually avoided; if you take both, contact your pharmacist or doctor so they can adjust your plan or monitor you closely.

Here's what's going on. One of your medicines, abrocitinib (Cibinqo), can slow down a natural "pump" in your body that normally helps push out the other medicine, repotrectinib (Augtyro). When that pump is blocked, more repotrectinib can build up in your blood than intended.

The concern is that higher levels of repotrectinib can mean more, or stronger, side effects. This is considered a serious pairing, which is why doctors usually try to avoid using them together. The good news is your care team can manage this by adjusting your plan or choosing a different option. Please don't stop either medicine on your own, just talk with your pharmacist or doctor.

Effect: Increased repotrectinib exposure and risk of repotrectinib-related adverse effects.

Mechanism: Abrocitinib inhibits P-gp-mediated efflux of repotrectinib (a P-gp substrate), reducing clearance and raising systemic exposure. Neither is a prodrug here; effect is a direct increase in active repotrectinib.

Magnitude: Not established for abrocitinib. A strong CYP3A/P-gp inhibitor (itraconazole) raised repotrectinib AUC ~5.9-fold and Cmax ~1.7-fold; abrocitinib is a weaker/selective P-gp inhibitor, so effect may be smaller but is still relevant.

  • Evidence: Probable. Onset: unspecified.
  • Management: Avoid concomitant use where possible; if unavoidable, individualize dosing and monitor closely for repotrectinib toxicity.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects

Interaction Deep Dive

Do not administer repotrectinib together with P-gp inhibitors. When repotrectinib is taken alongside a P-gp inhibitor, repotrectinib exposure can rise, potentially heightening both the frequency and the severity of repotrectinib adverse reactions. During drug interaction studies, coadministration with itraconazole (a strong inhibitor of both CYP3A and P-gp) produced a 5.9-fold rise in repotrectinib AUC (0 to inf) and a 1.7-fold rise in Cmax1.

Why it happens (mechanism)

Inhibition of P-gp-mediated efflux transport of repotrectinib

How to manage this interaction

What your care team may do:

  • Because this is a major interaction, prescribers often try to avoid using these two together, or choose an alternative to one of them.
  • If both are truly needed, your team may individualize the repotrectinib dose and monitor you more closely for side effects.

What you should do:

  • Keep taking both exactly as prescribed unless your doctor tells you otherwise.
  • Make sure your pharmacist and prescriber know you take both, and ask whether one should be changed.
  • Report any new or worsening side effects promptly.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) In the drug interaction studies, when repotrectinib was given together with itraconazole (a strong inhibitor of CYP3A and P-gp), its AUC (0 to inf) rose by 5.9-fold and its Cmax rose by 1.7-fold 1.

Common questions

Can I take Abrocitinib and Repotrectinib together?

Abrocitinib can raise repotrectinib levels and side-effect risk, so this combination is usually avoided; if you take both, contact your pharmacist or doctor so they can adjust your plan or monitor you closely. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Abrocitinib and Repotrectinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Abrocitinib and Repotrectinib interaction managed?

What your care team may do: Because this is a major interaction, prescribers often try to avoid using these two together, or choose an alternative to one of them. If both are truly needed, your team may individualize the repotrectinib dose and monitor you more closely for side effects. What you should do: Keep taking both exactly as prescribed unless your doctor tells you otherwise. Make sure your… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Abrocitinib or Repotrectinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: AUGTYRO(TM) oral capsules, repotrectinib oral capsules. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.